Trecetilide is a class III antiarrhythmic agent developed for the treatment of atrial flutter and fibrillation. Trecetilide probably has effects on the cardiac myocyte membrane that are similar to ibutilide. It is being developed for both oral and intravenous administration. Unlike ibutilide, trecetilide has good oral bioavailability. Trecetilide has a good metabolic stability. As with ibutilide, its mechanism of class III action may involve both rectifier K+ current blockade and other mechanisms of prolonging repolarization.

2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitize, is used in photodynamic therapy. It has been shown the therapeutic potential of HPPH in phase II clinical trials for the treatment of esophageal cancer. Besides, HPPH participated in clinical trials in treating patients with advanced non-small cell lung cancer that blocks the air passages. However, these studies were terminated.

Vinformide (also known as N-formylleurosine), an N-formyl analog of leurosine possesses antineoplastic activity. This drug was studied for the treatment of lymphoma, leukemia and Hodkin’s disease. However, studies were discontinued, because vinformide exerted an acute cardiotoxic side effect.

IRINDALONE is an antihypertensive agent. It is a serotonin receptor antagonist with weak alpha 1-adrenoceptor blocking properties.

Otimerate, an antifungal and antibacterial agent was used as a preservative for serum and bone. Information about the current use of this compound is not available.

Iomazenil (also known as Ro16-0154, benzodine) is a partial inverse agonist of central-type benzodiazepine receptors (BZR) which binds specifically to BZR with high affinity and a potential treatment for alcohol abuse. The compound was introduced in 1989 by pharmaceutical company Hoffmann-La Roche as an Iodine-123-labelled SPECT tracer for imaging benzodiazepine receptors (GABAA receptors) in the brain.

Vinleucinol (also known as vinblastine-isoleucinate or V-LEU) was developed as a vinca alkaloid derivative. This compound exhibited superior antitumor activity in malignant melanoma, small cell lung carcinoma, and breast cancer lines. Experiments on animals have shown that metabolite of vinleucinol was mainly responsible for the antitumor.

Dolastatin 10 is an unusual peptide of marine origin which binds to tubulin, inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. Dolastatin 10 has been used in trials phase II studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, among others. In case of hormone-refractory prostate cancer, it lacks significant clinical activity as a single agent and also dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.

Tetraisopropyl 2-(3,5-Di-Tert-Butyl-4-Hydroxyphenyl)Ethyl-1,1-Biphosphonate (also known as SR-9223I and SR 45023A) is a gem-diphosphonate derivative patented by Symphar S. A. as an antihypertensive and anti-inflammatory agent. Tetraisopropyl 2-(3,5-Di-Tert-Butyl-4-Hydroxyphenyl)Ethyl-1,1-Biphosphonate acts as 3-hydroxy-3-methylglutaryl reductase inhibitor, besides that SR-9223I suppresses acyl-CoA: cholesterol acyltransferase activity and prevents the oxidation of plasma lipoproteins. In preclinical studies, SR-9223i reduces blood cholesterol concentrations in mice, hamsters, dogs, and monkeys. SR-9223i inhibits the growth of a wide variety of tumor cell lines in vitro and triggered apoptosis in HL60 cells in less than 2 h. SR-9223i induces caspase-3 activity at concentrations similar to it’s IC(50) values for cell proliferation. Unfortunately, in clinical trials SR-9223I failed to demonstrate efficacy in patients with refractory melanoma and further development was discontinued.